Standard BioTools (STU:FLB) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Standard BioTools Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Standard BioTools is: No Data: Cannot be evaluated.

Competitive Comparison of Standard BioTools's Risk Assessment

For the Diagnostics & Research subindustry, Standard BioTools's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Standard BioTools's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Standard BioTools's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Risk Assessment falls into.

Standard BioTools (STU:FLB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Standard BioTools Risk Assessment Related Terms

Thank you for viewing the detailed overview of Standard BioTools's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Standard BioTools (STU:FLB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Standard BioTools Inc (STU:FLB) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

LAB:USA FLB:Germany

Address

2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080

Website

https://www.standardbio.com

Standard BioTools Inc manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. The company's segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Standard BioTools (STU:FLB) Headlines

No Headlines